AMGEN INC
AMGNNASDAQ🏆 #57 by market capEarnings Nov 3 · PostBiotech
$414.34▼ $2.86 (−0.69%)
Live1h—
24h▼ 0.7%
7d▲ 1.6%
14d▲ 6.9%
30d▲ 14.9%
1y▲ 45.5%
🏦Market Cap
$223.62B
Large Cap
📈Revenue Growth (YoY)
+9.1%
Slowing
📊Gross Margin
74.3%
High
💵FCF Margin
28.1%
Strong
⚖️P/S Ratio
5.8x
Fair
Otter Score
54
Weak
Trading Snapshot
- Day Range
- $410.56 – $417.67
- 52-Week Range
- $269.77 – $418.40
- Volume
- $6.81B
- Avg Volume
- $5.13B
- Shares Outstanding
- 539.7M
- Next Earnings
- Sep 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $38.67B
- Last Q Revenue
- $9.14B
- P/E Ratio
- 25.4
- P/S Ratio
- 5.8x
- EPS (TTM)
- $16.10
- Dividend Yield
- 2.34%
Why Investors Own AMGN
- ✓High-growth profile — revenue up +17.9% YoY with expanding Biotech exposure.
- ✓Healthy economics — 74% gross margin and 4% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$38.67B▲ +20.8% YoY
Gross Margin (TTM)
73.8%▲ +4.1% YoY
Operating Income (TTM)
$9.67B▲ +20.8% YoY
Free Cash Flow (TTM)
$1.59B▲ +20.8% YoY
About AMGEN INC
A company profile for AMGEN INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Price Target
ⓘAverage Target
$432.90
▲ +4.5% Upside
High Target$506.18
Low Target$339.52
Based on 17 analysts
Latest News & Updates
🚀
Barron’s·2h ago
AMGEN INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift AMGN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
AMGEN INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.